Key PointsDaratumumab plus chemotherapy may effectively bridge children and young adults with relapsed/refractory T-cell ALL/LL to HSCT.No new safety conce
Richard J. Bleicher, MD, FACS, Chief of the Division of Breast Surgery and Clinical Director of the Breast Service Line at Fox Chase Cancer Center.
The AACR June L. Biedler Prize for Cancer Journalism is a program of the AACR to raise awareness of the critical role that the media…
Help The Skin Cancer Foundation purchase and customize a new RV to keep our Destination Healthy Skin program on the road.
#ASHinaFlash, your fast track to essential #ASH24 content! Get expert highlights of must-see sessions and quick takes on the latest #hematology breakthroughs…
Chelsey Schlechter, MPH, PhD, has been chosen as a Cancer Moonshot Scholar. She is one of eleven researchers from across the country who have been…
Key PointsELN 2017 and 2022 prognostic classifiers did not adequately stratify OS outcomes for patients with AML treated with venetoclax-azacitidine.A 4-ge
PURPOSEGuidelines recommend cardiovascular (CV) risk assessment and counseling for cancer survivors. This study evaluated the automated heart-health assessment (AH-HA) clinical decision support tool to promote…
A BLA has been accepted by the FDA for 2 belantamab mafodotin combinations that have shown positive results in patients with multiple myeloma.
Testing for inherited cancer risk has become more accessible, affordable and accurate. Fred Hutch clinicians and researchers explain why it can be important, how to…
Health Canada has approved cilta-cel for use in patients with relapsed/lenalidomide-refractory multiple myeloma following 1 to 3 prior lines of therapy.
